|
||
Palovir Actions |
||
Pharmacology: Palovir is converted to Palovir monophosphate, a nucleotide, by the viral thymidine kinases of herpes simplex virus (HSV) and varicella-zoster virus (VZV). Palovir monophosphate is converted to the diphosphate by cellular guanylate kinase and to the triphosphate by a number of cellular enzymes. Palovir triphosphate interferes with HSV and VZV deoxyribonucleic acid (DNA) polymerase and inhibits viral DNA replication. The triphosphate can be incorporated into growing chains of DNA by viral DNA polymerase, resulting in the termination of the DNA chain. Palovir is therefore selectively converted to the active triphosphate form by the HSV- and VZV-infected cells.
Palovir crosses the placenta and is excreted through the kidney and in breast milk. The terminal t½ is reported to be 2-3 hrs for adults without renal impairment. The t½ increases in patients with renal impairment.
Palovir is poorly absorbed from the gastrointestinal tract. It is not significantly affected by food.
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Viral (HSV-1, HSV-2 and VZV) thymidine kinase converts Palovir to the Palovir monophosphate, which is then converted to the diphosphate by cellular guanylate kinase, and finally to the triphosphate by phosphoglycerate kinase, phosphoenolpyruvate carboxykinase, and pyruvate kinase. Palovir triphosphate competitively inhibits viral DNA polymerase and competes with the natural deoxyguanosine triphosphate, for incorporation into viral DNA. Once incorporated, Palovir triphosphate inhibits DNA synthesis by acting as a chain terminator.
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|